Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to clinically evaluate the spleen during PBPC mobilization by filgrastim in normal donors.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Lenograstim

Criteria

Inclusion Criteria: - Eligible to be PBPC donor for allogeneic transplantation as determined by local institution Exclusion Criteria: - History of splenectomy - Previous PBPC mobilization attempts - Previous treatment with GCSF or GMCSF